<DOC>
	<DOCNO>NCT00752856</DOCNO>
	<brief_summary>CCTG 589 randomize , open-label , pilot study compare efficacy , safety tolerability RAL plus LPV/r EFV plus TDF/FTC HIV-infected , treatment-naïve subject . Subjects ineligible evidence drug resistant virus past time screening ( never previously test ) . Those find eligible randomized 1:1 initiate either LPV/r ( 400/100 mg ) plus RAL ( 400mg ) , give twice-daily , fix dose combination EFV ( 600 mg ) , TDF ( 300 mg ) FTC ( 200 mg ) give once-daily Atripla® 48 week . Hypotheses 1 . The novel nucleoside-sparing combination LPV/r + RAL faster phase 1 viral decay rate compare standard-of-care therapy EFV/TDF/FTC antiretroviral-naïve patient . 1 . Faster phase 1 viral decay dynamic associate improved longer-term ( week 48 ) viral suppression . 2 . Faster phase 1 viral decay dynamic associate accelerate early ( Day 0-14 ) clearance cell-associated HIV DNA . 3 . Faster phase 1 viral decay dynamic associate great early ( baseline week 12 ) CD4+ T-cell recovery . 2 . The LPV/r + RAL arm great decrease early ( baseline week 4 ) CD4/CD8 T-cell immune activation apoptosis associate great late ( week 12 week 48 ) CD4+ T-cell recovery . 3 . Subjects treat LPV/r + RAL arm small change total cholesterol triglyceride baseline receive EFV/TDF/FTC .</brief_summary>
	<brief_title>Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine Treatment Naive Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Documented HIV1 infection . Treatment naïve ( define never receive HIV antiretroviral agent past ) . CD4+ Tcell count great equal 50 cells/mm3 HIV viral load great equal 5,000 copies/mL Laboratory value obtain screen laboratory within 30 day entry : Absolute neutrophil count ( ANC ) great 750/mm3 . Hemoglobin great 8.0 g/dL . Platelet count great 50,000/mm3 . Calculated creatinine clearance ( CrCl ) &gt; 60 mL/min estimate CockcroftGault equation : For men , ( 140 age year ) x ( body weight kg ) ÷ ( serum creatinine mg/dL x 72 ) = CrCl ( mL/min ) For woman , multiply result 0.85 = CrCl ( mL/min ) AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase le 5 x ULN . Total bilirubin le 2.5 x ULN . Females childbearing potential must negative serum pregnancy test screen agree use doublebarrier method contraception throughout study period . Men woman age great equal 18 year . Ability obtain prescription HIV antiretroviral medication require prescription fill prior entry . Ability willingness subject give write informed consent Pregnancy breastfeed Serious illness require systemic treatment and/or hospitalization subject either complete therapy clinically stable therapy , opinion investigator , least 30 day prior study entry ( day 0 ) . Acute therapy serious infection serious medical illness ( judgment site investigator ) require systemic treatment and/or hospitalization within 14 day prior study entry ( day 0 ) . Evidence HIV seroconversion within 6 month prior study entry . Evidence major HIV drug resistanceassociated mutation genotype perform prior study entry time screen . History chronic hepatitis C ( define HCV antibody positive HCV RNA detectable ) . History chronic active hepatitis B ( defined surface antigen positive and/or HBV DNA detectable ) . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement . Use immunomodulator , HIV vaccine , investigational therapy within 30 day study entry . Use human growth hormone within 30 day prior study entry . Initiation testosterone anabolic steroid within 30 day prior study entry . ( Exception : Chronic replacement dosages patient 's diagnosed hypogonadism allow ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>HIV treatment</keyword>
	<keyword>Treatment-naive</keyword>
	<keyword>Adult</keyword>
</DOC>